It is notable that IFNα therapy for hepatitis C is a documented risk factor for developing sarcoidosis (approximately 5% of cases) [30]; and IFNß therapy has also been associated with case reports of sarcoidosis [31]. The gene discussed is IFNA1; the disease is sarcoidosis.